EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 181 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... February 13, 2023 FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer April 26, 2024 Hormone therapy gets green light for advanced prostate cancer September 14, 2021 Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes June 3, 2022 Load more HOT NEWS Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in... 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ How serendipity sent this oncologist in search of a cure for...
